Strs Ohio Makes New $2.05 Million Investment in Moderna, Inc. $MRNA

Strs Ohio acquired a new stake in Moderna, Inc. (NASDAQ:MRNA) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 72,280 shares of the company’s stock, valued at approximately $2,049,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. S Bank Fund Management Ltd bought a new stake in shares of Moderna in the first quarter worth about $25,000. SVB Wealth LLC acquired a new stake in shares of Moderna in the first quarter valued at approximately $28,000. Costello Asset Management INC acquired a new stake in Moderna during the 1st quarter worth approximately $30,000. Sentry Investment Management LLC acquired a new position in Moderna in the 1st quarter valued at $31,000. Finally, Deseret Mutual Benefit Administrators raised its holdings in Moderna by 53.3% in the 1st quarter. Deseret Mutual Benefit Administrators now owns 1,128 shares of the company’s stock valued at $32,000 after acquiring an additional 392 shares in the last quarter. Institutional investors own 75.33% of the company’s stock.

Moderna Trading Up 1.6%

Shares of NASDAQ:MRNA opened at $23.88 on Tuesday. Moderna, Inc. has a 12 month low of $23.15 and a 12 month high of $75.37. The company has a 50-day moving average price of $28.22 and a 200 day moving average price of $28.10. The company has a market cap of $9.29 billion, a price-to-earnings ratio of -3.17 and a beta of 1.93.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Friday, August 1st. The company reported ($2.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.99) by $0.86. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. The company had revenue of $142.00 million for the quarter, compared to analyst estimates of $116.26 million. During the same period last year, the company posted ($3.33) earnings per share. Moderna’s revenue was down 41.1% compared to the same quarter last year. Moderna has set its FY 2025 guidance at EPS. As a group, equities analysts forecast that Moderna, Inc. will post -9.61 EPS for the current year.

Analyst Upgrades and Downgrades

MRNA has been the topic of a number of analyst reports. Morgan Stanley reiterated an “equal weight” rating and issued a $32.00 price target on shares of Moderna in a research report on Friday, August 1st. Citigroup initiated coverage on Moderna in a research report on Friday, August 1st. They set a “neutral” rating and a $40.00 price target for the company. JPMorgan Chase & Co. set a $26.00 target price on Moderna in a research report on Friday, August 1st. William Blair reissued a “market perform” rating on shares of Moderna in a research note on Monday, June 2nd. Finally, Evercore ISI set a $32.00 price target on Moderna in a research note on Friday, August 1st. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, fourteen have assigned a Hold rating and four have issued a Sell rating to the stock. Based on data from MarketBeat.com, Moderna presently has an average rating of “Hold” and a consensus price target of $41.81.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.